Monitoring of plasma levels of activated protein C using a clinically applicable oligonucleotide-based enzyme capture assay

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 3, 2012, Pages 390-398

  Muller J ^a   Friedrich, M ^a   Becher, T ^a   Braunstein, J ^a   Kupper, T ^a   Berdel, P ^a   Gravius, S ^a   Rohrbach, F ^b   Oldenburg, J ^a   Mayer, G ^b   Potzsch B ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Activated protein C; Aptamer; Enzyme capture assay; Oligonucleotide based enzyme capture assay

Indexed keywords

ACTIVATED PROTEIN C; APROTININ; OLIGONUCLEOTIDE; THROMBIN;

ACTIVATED PROTEIN C OLIGONUCLEOTIDE BASED ENZYME CAPTURE ASSAY; ACTIVATED PROTEIN C PLASMA LEVEL; ARTICLE; ENZYME ASSAY; ENZYME BLOOD LEVEL; HIP ARTHROPLASTY; HUMAN; HYDROLYSIS; LIMIT OF QUANTITATION; OLIGONUCLEOTIDE PROBE; PATIENT MONITORING; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN BLOOD LEVEL; SURGICAL PATIENT; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; APTAMERS, NUCLEOTIDE; ARTHROPLASTY, REPLACEMENT, HIP; BIOLOGICAL MARKERS; BLOOD COAGULATION TESTS; CHROMOGENIC COMPOUNDS; CLINICAL ENZYME TESTS; FEMALE; HUMANS; HYDROLYSIS; LIMIT OF DETECTION; MALE; MIDDLE AGED; MONITORING, INTRAOPERATIVE; PREDICTIVE VALUE OF TESTS; PROTEIN C; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THROMBIN; TIME FACTORS; UP-REGULATION;

EID: 84857560034     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04623.x     Document Type: Article

References (24)

1. Esmon CT. Do-all receptor takes on coagulation, inflammation. Nat Med 2005; 11: 475-7.
2. Esmon CT. The Protein C pathway. Chest 2003; 124: 26S-32S.
3. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296: 1880-2.
4. Esmon CT. The discovery of the endothelial cell protein C receptor. J Thromb Haemost 2010; 8: 2-5.
5. Rezaie AR. Regulation of the protein C anticoagulant and anti-inflammatory pathways. Curr Med Chem 2010; 17: 2059-69.
6. Ruf W. New players in the sepsis-protective activated protein C pathway. J Clin Invest 2010; 120: 3084-7.
7. Gruber A, Griffin JH. Direct detection of activated protein C in blood from human subjects. Blood 1992; 79: 2340-8.
8. Orthner CL, Kolen B, Drohan WN. A sensitive and facile assay for the measurement of activated protein C activity levels in vivo. Thromb Haemost 1993; 69: 441-7.
9. Liaw PCY, Ferrell G, Esmon CT. A monoclonal antibody against activated protein C allows rapid detection of activated protein C in plasma and reveals a calcium ion dependent epitope involved in factor Va inactivation. J Thromb Haemost 2003; 1: 662-70.
10. Esmon CT, Ferrell GL, Liaw PCY. Assay for rapid detection of human activiated protein C and highly specific monoclonal antibody therefor. U.S. patent 6989241. Accessed August 8, 2011.
11. Strandberg K, Kjellberg M, Knebel R, Lilja H, Stenflo J. A sensitive immunochemical assay for measuring the concentration of the activated protein C-protein C inhibitor complex in plasma: use of a catcher antibody specific for the complexed/cleaved form of the inhibitor. Thromb Haemost 2001; 86: 604-10.
12. Strandberg K, Svensson A, Stenflo J. Stabilyte tubes contain strongly acidic citrate prevent in vitro complex formation between activated protein C and protein C inhibitor. Thromb Haemost 2003; 89: 947-9.
13. Schulman S, Eelde A, Blombäck M, Stenflo J. The plasma concentration of activated protein C appears normal in patients with haemophilia. Haemophilia 2009; 15: 566-70.
14. España F, Vicente V, Tabernero D, Scharrer I, Griffin JH. Determination of plasma protein C inhibitor and of two activated protein C-inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease. Thromb Res 1990; 59: 593-608.
15. Alcaraz A, España F, Sánchez-Cuenca J, Zuazu I, Estellés A, Aznar J, Vicente V. Activation of the protein C pathway in acute sepsis. Thromb Res 1995; 79: 83-93.
16. España F, Vayá A, Mira Y, Medina P, Estellés A, Villa P, Falcó C, Aznar J. Low level of circulating activated protein C is a risk factor for venous thromboembolism. Thromb Haemost 2001; 86: 1368-73.
17. Müller J, Isermann B, Dücker C, Salehi M, Meyer M, Friedrich M, Madhusudhan T, Oldenburg J, Mayer G, Pötzsch B. An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor. Chem Biol 2009; 16: 442-51.
18. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
19. Simioni P, Kalafatis M, Millar DS, Henderson SC, Luni S, Cooper DN, Girolami A. Compound heterozygous protein C deficiency resulting in the presence of only the beta-form of protein C in plasma. Blood 1996; 88: 2101-8.
20. Grinnell BW, Walls JD, Gerlitz B. Glycosylation of human protein C affects its secretion, processing, functional activities, and activation by thrombin. J Biol Chem 1991; 266: 9778-85.
21. Gil GC, Velander WH, van Cott KE. N-glycosylation microheterogeneity and site occupancy of an Asn-X-Cys sequon in plasma-derived and recombinant protein C. Proteomics 2009; 9: 2555-67.
22. Gomez K, McVey JH, Tuddenham E. Inhibition of coagulation by macromolecular complexes. Haematologica 2005; 90: 1570-6.
23. España F, Estelles A, Griffin JH, Aznar J, Gilabert J. Aprotinin (trasylol) is a competitive inhibitor of activated protein C. Thromb Res 1989; 56: 751-6.
24. Taby O, Chabbat J, Steinbuch M. Inhibition of activated protein C by aprotinin and the use of the insolubilized inhibitor for its purification. Thromb Res 1990; 59: 27-35.